Eloralintide: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข2 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Storage conditions for the clinical trial formulation have not been publicly disclosed. Peptide-based therapies typically require refrigerated storage (2-8 degrees C).
Protocol Quick-Reference
Obesity and overweight (investigational)
Dosing
Amount
1-9 mg once weekly
Frequency
Once weekly
Duration
48+ weeks
Step-wise Titration (12 weeks)
Administration
Route
SCSchedule
Once weekly
Timing
Consistent day of week; dose escalation may improve tolerability
โ Rotate injection sites
Cycle
Duration
Ongoing
Repeatable
Yes
Preparation & Storage
โ Ready-to-use โ no reconstitution required
Storage: Refrigerate at 2-8 degrees C (expected based on peptide formulation).
โ๏ธ Suggested Bloodwork (4 tests)
When:
Why:
When:
Why:
When:
Why:
When:
Why:
๐ก Key Considerations
- โInvestigational drug - not approved by any regulatory authority
- โDose escalation may reduce GI adverse events compared with starting at higher doses
- โHigher doses produce greater weight loss but with increased side effect burden
- โPhase 2 excluded patients with type 2 diabetes
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Obesity Monotherapy (Phase 2 Fixed Dose) | 1 mg, 3 mg, 6 mg, or 9 mg subcutaneously once weekly. The 9 mg fixed dose achieved the greatest weight loss (20.1% at 48 weeks). | Once weekly subcutaneous injection | 48 weeks (Phase 2 trial duration) | Higher doses produced greater weight loss but with increased incidence of nausea and fatigue. The 9 mg dose achieved 20.1% weight loss but had nausea rates of approximately 64%. |
| Obesity Monotherapy (Phase 2 Dose Escalation) | Stepwise escalation from 3 mg to 6 mg to 9 mg, or from 6 mg to 9 mg, over the 48-week treatment period. | Once weekly subcutaneous injection | 48 weeks (Phase 2 trial duration) | Dose escalation regimens reduced the incidence of GI adverse events compared with starting at higher fixed doses. The 6-to-9 mg arm achieved 15.8% weight loss with improved tolerability. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Eloralintide was administered as a pre-filled subcutaneous injection in clinical trials. Specific formulation details have not been publicly disclosed. As an investigational compound, it is not commercially available.
Recommended Injection Sites
- โAbdomen
- โThigh
- โUpper arm
๐งStorage Requirements
Storage conditions for the clinical trial formulation have not been publicly disclosed. Peptide-based therapies typically require refrigerated storage (2-8 degrees C).
Community Dosing Protocols
Compare these clinical doses with what 10+ community members report using.
Based on 10+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Investigational Status#
Eloralintide (LY3841136) is an investigational medication developed by Eli Lilly that has not received regulatory approval from any authority. All dosing information is derived from clinical trial protocols and published study results. Eloralintide is not commercially available and is accessible only through clinical trial enrollment.
Clinical Trial Dosing#
Phase 2 Trial (Lancet 2025)#
The Phase 2 trial evaluated six active treatment arms in 263 adults with obesity or overweight:
Fixed-Dose Arms:
| Dose | Weight Loss (48 wk) | Nausea Rate | Fatigue Rate |
|---|---|---|---|
| 1 mg weekly | -9.5% | ~11% | ~0% |
| 3 mg weekly | -10.5% | ~19% | ~8% |
| 6 mg weekly | -13.8% | ~42% | ~22% |
| 9 mg weekly | -20.1% | ~64% | ~46% |
Dose Escalation Arms:
| Regimen | Weight Loss (48 wk) | Tolerability |
|---|---|---|
| 6 mg to 9 mg | -15.8% | Improved vs 9 mg fixed |
| 3 mg to 6 mg to 9 mg | -14.6% | Improved vs 9 mg fixed |
The dose-escalation regimens demonstrated that gradual dose increases reduced the peak incidence of nausea and fatigue while still achieving substantial weight loss.
Phase 1 Multiple Ascending Dose (DOM 2026)#
In the Phase 1 study of 100 participants over 12 weeks:
- Weight loss ranged from 2.6% to 11.3% across ascending dose groups
- Dose-proportional pharmacokinetics were confirmed
- GI adverse events were minimal across dose levels
Dose-Response Relationship#
The Phase 2 data demonstrate a clear dose-response relationship for both efficacy and tolerability:
- Efficacy: Weight loss increased with dose from 9.5% (1 mg) to 20.1% (9 mg)
- Nausea: Incidence increased from approximately 11% (1 mg) to 64% (9 mg)
- Dose escalation benefit: Starting at lower doses and escalating reduced peak GI adverse events
The optimal balance between efficacy and tolerability appears to involve dose escalation to the 6-9 mg range, though the Phase 3 dose selection has not been publicly disclosed.
Administration#
Route and Frequency#
- Subcutaneous injection, once weekly
- Pre-filled injection device used in clinical trials
- Consistent day of week recommended
Injection Sites#
- Abdomen
- Thigh
- Upper arm
- Site rotation recommended
Monitoring#
- Body weight at regular intervals
- Metabolic panel (glycemic markers, lipid profile)
- Assessment for GI tolerability
- Liver function tests at baseline and periodically
Context Within Anti-Obesity Medications#
Eloralintide dosing differs from GLP-1 receptor agonists in several respects:
| Parameter | Eloralintide | Semaglutide 2.4 mg | Tirzepatide |
|---|---|---|---|
| Route | SC weekly | SC weekly | SC weekly |
| Dose range | 1-9 mg | 0.25-2.4 mg | 2.5-15 mg |
| Escalation period | Under investigation | 16-20 weeks | 20 weeks |
| Mechanism | Amylin agonist | GLP-1 agonist | GLP-1/GIP agonist |
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Eloralintide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.